<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="decrease">
            <roleset id="decrease.01" name="make smaller&#x0A;" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing decrease&#x0A;" />
                    <role n="2" descr="location&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and glucose consumption have been significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and glucose consumption were significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA has significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA is observed to have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA was observed to have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption are significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption can be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption can have been significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption could be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption is able to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption is believed to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption is shown to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption may be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption may have been significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption might be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption was able to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption was believed to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption was shown to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption will be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption will have been significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption would be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA can have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA can significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA could significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is able to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is believed to have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is believed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is observed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is shown to have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is shown to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA may have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA may significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA might significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA significantly decreases glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA was able to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA was believed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA was shown to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA will significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA would significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA will have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Disruption of narL can decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Disruption of narL can have decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Disruption of narL could decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there could be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Disruption of narL decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Disruption of narL has decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Disruption of narL has the ability to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Disruption of narL is able to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Disruption of narL is believed to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Disruption of narL is shown to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Disruption of narL may decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Disruption of narL may have decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Disruption of narL might decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Disruption of narL was able to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Disruption of narL was believed to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Disruption of narL was shown to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Disruption of narL will decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Disruption of narL will have decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Disruption of narL would decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection can be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection can have been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection could be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection had been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is able to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is believed to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is shown to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection may be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection may have been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection might be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was able to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was believed to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was shown to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection will be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection will have been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection would be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content can be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content can have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content has been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content will be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and methionine content can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and methionine content can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and methionine content is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and methionine content is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and methionine content may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and methionine content may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and methionine content has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and methionine content could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and methionine content might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and methionine content was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and methionine content was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and methionine content will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and methionine content will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and methionine content would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Lipid peroxide synthesis can be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Lipid peroxide synthesis can have been decreased by treatment with melatonin, and have permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Lipid peroxide synthesis could be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Lipid peroxide synthesis has been decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Lipid peroxide synthesis is able to be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Lipid peroxide synthesis is believed to be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Lipid peroxide synthesis is decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Lipid peroxide synthesis is shown to be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Lipid peroxide synthesis may be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Lipid peroxide synthesis may have been decreased by treatment with melatonin, and have permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Lipid peroxide synthesis might be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Lipid peroxide synthesis was able to be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Lipid peroxide synthesis was believed to be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Lipid peroxide synthesis was decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>Lipid peroxide synthesis was shown to be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Lipid peroxide synthesis will be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Lipid peroxide synthesis will have been decreased by treatment with melatonin, and have permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Lipid peroxide synthesis would be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity can be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity could be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity has been decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity is able to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity is believed to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity is decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity may be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity might be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity was able to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity was believed to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity was decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity will be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity would be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation can decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation could decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation decreases promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation had the ability to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation has the ability to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation is able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation is believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation may decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation might decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation was able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation was believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation will decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation would decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Nitrite induction of the nirB promoter can be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Nitrite induction of the nirB promoter can have been decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Nitrite induction of the nirB promoter could be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Nitrite induction of the nirB promoter has been decreased by disruption of narL which has not been suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Nitrite induction of the nirB promoter is able to be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Nitrite induction of the nirB promoter is believed to be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Nitrite induction of the nirB promoter is decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Nitrite induction of the nirB promoter is shown to be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Nitrite induction of the nirB promoter may be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Nitrite induction of the nirB promoter may have been decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Nitrite induction of the nirB promoter might be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Nitrite induction of the nirB promoter was able to be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Nitrite induction of the nirB promoter was believed to be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Nitrite induction of the nirB promoter was decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>Nitrite induction of the nirB promoter was shown to be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>Nitrite induction of the nirB promoter will be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>Nitrite induction of the nirB promoter will have been decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>Nitrite induction of the nirB promoter would be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>The levels of Clara cell secretory protein can be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>The levels of Clara cell secretory protein can be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>The levels of Clara cell secretory protein can have been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>The levels of Clara cell secretory protein could be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>The levels of Clara cell secretory protein could be decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>The levels of Clara cell secretory protein has been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>The levels of Clara cell secretory protein is able to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>The levels of Clara cell secretory protein is able to be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>The levels of Clara cell secretory protein is believed to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>The levels of Clara cell secretory protein is believed to be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>The levels of Clara cell secretory protein is decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>The levels of Clara cell secretory protein is shown to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>The levels of Clara cell secretory protein is shown to be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>The levels of Clara cell secretory protein may be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>The levels of Clara cell secretory protein may have been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>The levels of Clara cell secretory protein might be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>The levels of Clara cell secretory protein might be decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>The levels of Clara cell secretory protein was able to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>The levels of Clara cell secretory protein was believed to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>The levels of Clara cell secretory protein was decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>The levels of Clara cell secretory protein was shown to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>The levels of Clara cell secretory protein will be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>The levels of Clara cell secretory protein will be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>The levels of Clara cell secretory protein will have been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>The levels of Clara cell secretory protein would be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>The levels of Clara cell secretory protein would be decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>The production of C51 microcin can decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>The production of C51 microcin could decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>The production of C51 microcin decreases or is absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>The production of C51 microcin had the ability to to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>The production of C51 microcin has decreased or been absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>The production of C51 microcin has the ability to to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>The production of C51 microcin is able to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>The production of C51 microcin is believed to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>The production of C51 microcin is shown to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>The production of C51 microcin may decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>The production of C51 microcin might decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>The production of C51 microcin was able to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>The production of C51 microcin was believed to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>The production of C51 microcin was shown to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>The production of C51 microcin will decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>The production of C51 microcin would decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>Treatment with melatonin can decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>Treatment with melatonin could decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>Treatment with melatonin decreases lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>Treatment with melatonin has decreased lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>Treatment with melatonin is able to decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>Treatment with melatonin is believed to decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>Treatment with melatonin is shown to decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>Treatment with melatonin may decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>Treatment with melatonin might decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>Treatment with melatonin was able to decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>Treatment with melatonin was believed to decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>Treatment with melatonin will decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>Treatment with melatonin would decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli can be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli can have been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli could be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli has been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is able to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is believed to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is shown to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli may be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli may have been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli might be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was able to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was believed to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was shown to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli will be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli will have been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli would be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>marA locus can decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>marA locus can have decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>marA locus could decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>marA locus decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>marA locus decreases expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>marA locus has decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>marA locus has the ability to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>marA locus is able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>marA locus is believed to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>marA locus is shown to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>marA locus may decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>marA locus may have decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>marA locus might decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>marA locus was able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>marA locus was believed to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>marA locus was shown to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>marA locus will decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>marA locus will have decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>marA locus would decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
